{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:47:52Z","timestamp":1782272872542,"version":"3.54.5"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>A case is reported in which the anti\u2013factor Xa activity of enoxaparin was measured during therapeutic plasma exchange (TPE).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>A 52-year-old male underwent TPE for antineutrophil cytoplasmic antibody\u2013associated vasculitis while receiving therapeutic enoxaparin. Enoxaparin anti\u2013factor Xa levels were measured before and immediately after TPE sessions as well as outside TPE sessions. The calculated enoxaparin half-life during TPE was 0.897 hours, whereas the calculated half-life outside TPE was 5.26 hours, demonstrating that the half-life of enoxaparin is dramatically shortened during TPE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Enoxaparin\u2019s anti\u2013factor Xa activity should be monitored and dosing schedules should be adjusted to ensure therapeutic enoxaparin levels in all patients receiving TPE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag004","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T10:49:34Z","timestamp":1767782974000},"page":"e479-e482","source":"Crossref","is-referenced-by-count":0,"title":["Effect of therapeutic plasma exchange on the anti\u2013factor Xa activity of enoxaparin: A case report"],"prefix":"10.1093","volume":"83","author":[{"given":"Thaddaus","family":"Hellwig","sequence":"first","affiliation":[{"name":"South Dakota State University College of Pharmacy and Allied Health Professions, Sanford USD Medical Center , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bri","family":"Jansma Vant Hul","sequence":"additional","affiliation":[{"name":"South Dakota State University College of Pharmacy and Allied Health Professions, Sanford USD Medical Center , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Schaar","sequence":"additional","affiliation":[{"name":"Sanford USD Medical Center , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawood","family":"Shehzad","sequence":"additional","affiliation":[{"name":"Sanford USD Medical Center , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoon","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Sanford USD Medical Center , Sioux Falls, SD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"issue":"1","key":"2026062323071148600_zxag004-B1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12028-020-00989-1","article-title":"Drug dosing in patients undergoing therapeutic plasma exchange","volume":"34","author":"Mahmoud","year":"2021","journal-title":"Neurocrit Care"},{"key":"2026062323071148600_zxag004-B2","author":"Enoxaparin"},{"issue":"4","key":"2026062323071148600_zxag004-B3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00001721-200006000-00012","article-title":"The effect of plasmapheresis on the serum activity level of dalteparin: a case report","volume":"11","author":"Sabloff","year":"2000","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"4","key":"2026062323071148600_zxag004-B4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1537-2995.2006.00755.x","article-title":"Anticoagulation with low-molecular-weight heparin (dalteparin) in plasmapheresis therapy: initial experience","volume":"46","author":"Schinzel","year":"2006","journal-title":"Transfusion"},{"issue":"4","key":"2026062323071148600_zxag004-B5","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1002\/phar.1907","article-title":"Effect of plasmapheresis on the anti-factor Xa activity of enoxaparin in an obese adolescent patient","volume":"37","author":"Rahawi","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"23","key":"2026062323071148600_zxag004-B6","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.2146\/ajhp170885","article-title":"Effect of plasma exchange on antifactor Xa activity of enoxaparin and serum levetiracetam levels","volume":"75","author":"Peters","year":"2018","journal-title":"Am J Health-Syst Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag004\/66288952\/zxag004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/13\/e479\/66288952\/zxag004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/13\/e479\/66288952\/zxag004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T03:07:27Z","timestamp":1782270447000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/13\/e479\/8416076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":6,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,1,7]]},"published-print":{"date-parts":[[2026,6,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag004","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,7,1]]},"published":{"date-parts":[[2026,1,7]]}}}